Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Genetic Diseases, Inborn 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Specimen Handling 17Magnetic Resonance Spectroscopy 15Gemcitabine 13Cisplatin 8Biopsy 8Radiotherapy 7Mitomycin 6Cystoscopy 6pembrolizumab 5Trastuzumab 5Paclitaxel 5Fluorouracil 5cabozantinib 4atezolizumab 4Radiation 4erdafitinib 3dehydroftorafur 3Transurethral Resection of Bladder 3Sunitinib 3Sorafenib 3Platinum 3Nivolumab 3Mitozytrex 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3valrubicin 2tipifarnib 2sapanisertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urinary Bladder Neoplasms × keyhole-limpet hemocyanin × Clear all
NCT00006034 2013-05-15

Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡